Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 6/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2146182 | 0.94 | EPHX2 (0.45) | EPHX2KMT2AALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL2018904 | 0.93 | ALDH1A1 (0.43) | EPHX2MEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL610387 | 0.88 | ALDH1A1 (0.50) | EPHX2KMT2AALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL1437590 | 0.85 | EPHX2 (0.49) | EPHX2ALDH1A1MAPK1L3MBTL1LMNA | |
| SCHEMBL26599493 | 0.83 | NOTUM (0.41) | ALDH1A1 | |
| SCHEMBL1609203 | 0.82 | PIK3CD (0.39) | — | |
| SCHEMBL23779158 | 0.78 | GAA (0.37) | ALDH1A1MAPK1LMNAGAATDP1 | |
| SCHEMBL1437900 | 0.76 | SMO (0.37) | EPHX2ALDH1A1MAPK1L3MBTL1LMNA | |
| SCHEMBL28060419 | 0.75 | MAPK1 (0.44) | EPHX2MEN1KMT2AALDH1A1MAPK1 | |
| SCHEMBL12713904 | 0.75 | MAPK1 (0.48) | EPHX2MEN1KMT2AALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110086853-A1 | Therapeutic Compounds | BROWN WILLIAM | 2011-04-14 | — | — | US | disclosed |
| US-7615642-B2 | Therapeutic compounds | ASTRAZENECA AB (SE) | 2009-11-10 | — | — | US | disclosed |
| US-20070244092-A1 | N-Cyclopropyl-1-{[2-(1,1-difluoroethyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl}-1H-pyrrole-3-carboxamide; for pain management | ASTRAZENECA AB (SE) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086853-A1 | Therapeutic Compounds | OPRL1, F12, F3 | EPHX2 2664/4885MEN1 1668/4885KMT2A 3546/4885 |
| US-20070244092-A1 | N-Cyclopropyl-1-{[2-(1,1-difluoroethyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl}-1H-pyrrole-3-carboxamide; for pain management | OPRM1, OPRL1, OPRK1 | EPHX2 3284/4885MEN1 3468/4885KMT2A 2100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.